Clinical Trial Update: Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Feasibility study evaluating chemoradiation with trastuzumab and pertuzumab in resectable HER2-positive esophageal carcinoma; study completed (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Carcinoma

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Esophageal Carcinoma | Phase 1, Phase 2 | Status: COMPLETED